Vizient has ranked Rush University Medical Center #1 for quality among the nation’s most prestigious academic medical centers. Learn more.

Excellence is just the beginning.

Translate

French German Italian Portuguese Russian

Maintenance Study For Patients With Residual Myeloma Post-Transplant

Clinical Trial Title: 
Phase II randomized trial of continuation of post-transplant maintenance with single-agent lenalidomide vs. consolidation/maintenance with ixazomib-lenalidomide-dexamethasone in patients with residual myeloma.
Clinical Trial Protocol ID: 
15071603
Clinical Trial Investigator Name: 
Agne Paner, MD
Clinical Trial Protocol Description: 

The purpose of this study is to compare two maintenance strategies for patients with residual multiple myeloma after autologous bone marrow transplant: standard of care single agent lenalidomide versus investigational combination of lenalidomide, ixazomib and dexamethasone.

Clinical Trial Eligibility Criteria: 

In order to participate you must meet the following criteria:

  • Have completed induction treatment followed by autologous stem cell transplant as initial therapy for asymptomatic myeloma as per the following IMWG criteria and initiated revlimid maintenance:
    1. Have initiated lenalidomide maintenance at approximately 3 months post autologous stem transplant (preferably 70-90 but not more than 120 days).
    2. Are receiving lenalidomide 10mg or 15mg and be able to tolerate dose escalation to 25mg daily.
    3. Have received lenalidomide maintenance for 3 months (+1month window for maximum of 4 months lenalidomide prior to enrollment.
  • Have no evidence of progressive disease on lenalidomide.
  • Have any measureable residual disease at the time of screening for the study, documented in at least one of the following ways:
    1. SPEP/IFIX positive disease.
    2. Freelite only positive disease.
    3. SPEP/IFIX-negative and Freelite- negative but MRD – positive disease is allowed.

You will be excluded from the study if any of the following criteria apply to you:

  • Have already started or received multi-drug consolidation regimen post-transplant except for lenalidomide maintenance.
  • Have moderate diarrhea (> grade 1).
  • Have known GI disease of GI procedure that could interfere with the oral absorption or tolerance of ixazomib including difficulty swallowing.
  • Have severe neuropathy (> grade 3 peripheral neuropathy, or grade 2 with pain).

This is a partial list of inclusion and exclusion criteria.

Clinical Trial Area: 
Blood Disorders and Hematologic Cancers
Contact Phone: 
(312) 942-4685
Contact Name: 
Christine Deskovich RN, BSN, OCN